Integra LifeSciences Retains Buy Rating and 4 Stock Analyses Making Headlines

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Integra LifeSciences Holdings Corporation (NASDAQ:IART) price target has been increased by Lazard Capital to $48 from $44 after its meetings with management causing its optimism to rise regarding the company. The firm believes that Integra has the ability to beat consensus expectations during the second half of 2012 and believes that the company’s October 24 analyst day may be a small catalyst for shares. Lazard Capital maintains its Buy rating on the stock, closing yesterday at $41.30 per share.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) price target has been increased to $75 from $57 by Lazard Capital.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Celgene Corporation (NASDAQ:CELG): Cantor believes that clinical events during Q4 not related to Celgene’s Revlimid drug may both raise Celgene’s multiple and cause it appreciation to its shares. The firm keeps its Buy rating and a $82 target on the stock.

Zimmer Holdings, Inc. (NYSE:ZMH): Piper Jaffray does not believe that the warning letter that was revealed last night by Zimmer will show much effect to the company’s operating results. The firm recommends using any near-term weakness as an opportunity to buy. The firm keeps its Overweight rating on the stock.

Senomyx Inc. (NASDAQ:SNMX) fair value estimate was reduced by Janney because of the slower commercialization of S9632 than predicted. Shares have a Buy rating.

Don’t Miss: Gold & Silver: Protection Against the Fed’s Punch Bowl.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business